drugset / Trial / NCT04999787
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled study. About 90 liver disease subjects with moderate or above pruritus are planned to be enrolled. They will be randomized to two dose groups (0.3 μg/kg and 0.6 μg/kg) and a placebo control group at a 1:1:1 ratio, with about 30 subjects in each group.
Timeline
- Start
- 2021-09-16
- Primary completion
- 2022-08-03
- Completion
- 2022-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK21542 | Peptide | 0.3 ug/kg | — |
| Subject | HSK21542 | Peptide | 0.6 ug/kg | — |
Indications
No indication recorded.